ArticleHuman vaccines & immunotherapeutics2018

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.

Christelle Remy-Ziller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.